{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:58:19Z","timestamp":1781269099732,"version":"3.54.1"},"reference-count":62,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","award":["PHRC-21-0261"],"award-info":[{"award-number":["PHRC-21-0261"]}],"id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The DREAMSPHEN study (Dose REduction of Antipsychotics vs. Maintenance treatment in schizophrenia after Stratification based on psychotic PHENotype) aims to compare the benefits and risks of a hyperbolic tapering method for antipsychotics to the maintenance of antipsychotics in a sample of clinically stabilised patients with schizophrenia spectrum disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A sample of 288 patients will be recruited from 12 centres in France. Inclusion criteria are: diagnosis of schizophrenia spectrum disorder (according to the 5th version of the Diagnostic and Statistical Manual of mental disorders, DSM-5), minimum of 3 months remission of psychotic symptoms and in treatment with antipsychotic medication (except clozapine and long-acting antipsychotic injection). First, the psychotic phenotype of the patients (cycloid psychosis vs other psychotic phenotype) will be assessed. Then, patients will be randomised either to the maintenance of treatment (MT) or to the antipsychotics dose reduction (DR) arm. DR will follow a hyperbolic schema according to Horowitz protocol. Patients will be assessed at baseline, and every 2\u2009months until 24 months follow-up regarding social functioning, psychotic and negative symptoms, side effects of antipsychotic medication, cognitive functioning, patient satisfaction, substance and alcohol use, and quality of life. The primary outcome will be a good social functioning after 24 months defined as a score at the Personal and Social Performance Scale &gt;70. Secondary outcome measures will include: psychotic and negative symptoms, hospitalisation for psychotic episode, antipsychotic dose, antipsychotic side effects, withdrawal symptoms, cognitive functioning, patient\u2019s well-being and quality of life. Safety measures will include death, admissions to psychiatric hospital, psychotic relapses and severe self-harm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The DREAMSPHEN trial aims to better identify patients with psychotic disorders who are most likely to benefit from antipsychotic tapering with an aim to inform future clinical treatment guidelines for antipsychotic treatment. DREAMSPHEN V2.0 of the 14 May 2025 has received ethical approval from Comit\u00e9 de protection des personnes Ile de France IV (N\u00b0 2023-509558-80-00) on 17 July 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      EU Clinical Trials Register \u2013 EudraCT no. 2023-509558-80-00. Clinical trials:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07152184\">NCT07152184<\/jats:ext-link>\n                      . Registered on 9 August 2025.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117593","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:05:38Z","timestamp":1781265938000},"page":"e117593","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["DREAMSPHEN: a randomised controlled study comparing dose reduction of antipsychotics vs maintenance treatment in schizophrenia spectrum disorder after stratification based on patients\u2019 psychotic phenotype \u2013 study protocol of a personalised medicine approach"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07152184","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-0629","authenticated-orcid":false,"given":"Fabrice","family":"Berna","sequence":"first","affiliation":[{"name":"Psychiatry department, H\u00f4pitaux Universitaires de Strasbourg;University of Strasbourg; Inserm U1329, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Abbie","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Research and Development Department, North East London NHS Foundation Trust, Ilford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Javelot","sequence":"additional","affiliation":[{"name":"Etablissement Public de Sant\u00e9 Alsace Nord, Brumath, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[{"name":"GMRC - Public Health Department, H\u00f4pitaux Universitaires de Strasbourg; University of Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R","family":"Foucher","sequence":"additional","affiliation":[{"name":"Noninvasive Neuromodulation Center, H\u00f4pitaux Universitaires de Strasbourg; University of Strasbourg; iCUBE - CNRS UMR 7357, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026061205052235000_16.6.e117593.1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2019.09.013","article-title":"Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms","volume":"215","author":"Shimomura","year":"2020","journal-title":"Schizophr Res"},{"key":"2026061205052235000_16.6.e117593.2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00406-020-01109-y","article-title":"Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial","volume":"271","author":"Huhn","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026061205052235000_16.6.e117593.3","doi-asserted-by":"crossref","unstructured":"Liu C-C , Hsieh MH , Chien Y-L , et al . Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort. Psychol Med 2023;1\u20139. doi:10.1017\/S0033291723000429","DOI":"10.1017\/S0033291723000429"},{"key":"2026061205052235000_16.6.e117593.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001861","article-title":"Antipsychotic Maintenance Treatment: Time to Rethink","volume":"12","author":"Moncrieff","year":"2015","journal-title":"PLoS Med"},{"key":"2026061205052235000_16.6.e117593.5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapsychiatry.2025.2525","article-title":"Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission","volume":"83","author":"Sommer","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026061205052235000_16.6.e117593.6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"key":"2026061205052235000_16.6.e117593.7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.schres.2021.04.011","article-title":"Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort","volume":"232","author":"Mayoral-van Son","year":"2021","journal-title":"Schizophr Res"},{"key":"2026061205052235000_16.6.e117593.8","doi-asserted-by":"crossref","first-page":"102135","DOI":"10.1016\/j.eclinm.2023.102135","article-title":"Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial","volume":"64","author":"Morant","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026061205052235000_16.6.e117593.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0573-7"},{"key":"2026061205052235000_16.6.e117593.10","doi-asserted-by":"crossref","unstructured":"Moncrieff J , Crellin N , Stansfeld J , et al . Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial. The Lancet Psychiatry 2023. doi:10.1016\/S2215-0366(23)00258-4","DOI":"10.1016\/S2215-0366(23)00258-4"},{"key":"2026061205052235000_16.6.e117593.11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"2026061205052235000_16.6.e117593.12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2019.08.035","article-title":"Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review","volume":"225","author":"Moncrieff","year":"2020","journal-title":"Schizophr Res"},{"key":"2026061205052235000_16.6.e117593.13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab017"},{"key":"2026061205052235000_16.6.e117593.14","doi-asserted-by":"crossref","unstructured":"Horowitz MA , O\u2019Neill J , Berna F , et al . Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be Important. Schizophr Bull 2025.:sbaf163. doi:10.1093\/schbul\/sbaf163","DOI":"10.1093\/schbul\/sbaf163"},{"key":"2026061205052235000_16.6.e117593.15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/eip.13144","article-title":"Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design","volume":"16","author":"Liu","year":"2022","journal-title":"Early Interv Psychiatry"},{"key":"2026061205052235000_16.6.e117593.16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2017.11.010","article-title":"Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review","volume":"197","author":"Bowtell","year":"2018","journal-title":"Schizophr Res"},{"key":"2026061205052235000_16.6.e117593.17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.31887\/DCNS.2020.22.1\/jfoucher","article-title":"Wernicke-Kleist-Leonhard phenotypes of endogenous psychoses: a review of their validity","volume":"22","author":"Foucher","year":"2020","journal-title":"Dialogues Clin Neurosci"},{"key":"2026061205052235000_16.6.e117593.18","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/14.4.633"},{"key":"2026061205052235000_16.6.e117593.19","doi-asserted-by":"publisher","DOI":"10.1080\/0954026021000016905"},{"key":"2026061205052235000_16.6.e117593.20","doi-asserted-by":"crossref","unstructured":"Leonhard K . Lassen sich die Schizophrenien klinisch und \u00e4tiologisch trennen? Zur Klassifikation Endogener Psychosen. Vienna: Springer, 1986:26\u201342.","DOI":"10.1007\/978-3-7091-9519-2_4"},{"key":"2026061205052235000_16.6.e117593.21","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291702007055"},{"key":"2026061205052235000_16.6.e117593.22","first-page":"51","article-title":"Acute treatment of cycloid psychosis: study on a sample of naive hospitalized patients with first-episode psychosis (FEP)","volume":"43","author":"Garc\u00eda-Andrade","year":"2015","journal-title":"Actas Esp Psiquiatr"},{"key":"2026061205052235000_16.6.e117593.23","first-page":"196","article-title":"Cycloid psychotic disorder: validation of the concept by means of a follow-up and a family study","volume":"23","author":"Maj","year":"1990","journal-title":"Psychopathology"},{"key":"2026061205052235000_16.6.e117593.24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1600-0447.1988.tb06320.x","article-title":"Clinical course and outcome of cycloid psychotic disorder: a three-year prospective study","volume":"78","author":"Maj","year":"1988","journal-title":"Acta Psychiatr Scand"},{"key":"2026061205052235000_16.6.e117593.25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00207390500064684","article-title":"Cycloid psychosis","volume":"17","author":"Peralta","year":"2005","journal-title":"Int Rev Psychiatry"},{"key":"2026061205052235000_16.6.e117593.26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/15622970410029925","article-title":"Differences in quality of life and course of illness between cycloid and schizophrenic psychoses - a comparative study","volume":"5","author":"Jabs","year":"2004","journal-title":"World J Biol Psychiatry"},{"key":"2026061205052235000_16.6.e117593.27","first-page":"156","article-title":"Long-Term Prognosis and Course of Schizo-Affective, Schizophreniform, and Cycloid Psychoses","volume":"16","author":"Armbruster","year":"1983","journal-title":"Psychiatr Clin (Basel)"},{"key":"2026061205052235000_16.6.e117593.28","first-page":"205","article-title":"Prognostic validity of the cycloid psychoses. A prospective follow-up study","volume":"23","author":"Beckmann","year":"1990","journal-title":"Psychopathology"},{"key":"2026061205052235000_16.6.e117593.29","first-page":"259","article-title":"Catamnesis of Endogenous Psychoses according to the Differential Diagnostic Method of Karl Leonhard","volume":"23","author":"Trostorff","year":"1990","journal-title":"Psychopathology"},{"key":"2026061205052235000_16.6.e117593.30","doi-asserted-by":"crossref","unstructured":"Albert E . \u00dcber den Einflu\u00df von neuroleptischer Langzeitmedikation auf den Verlauf von phasischen und remittierenden Unterformen endogener Psychosen. Zur Klassifikation Endogener Psychosen. Vienna: Springer, 1986:97\u2013107.","DOI":"10.1007\/978-3-7091-9519-2_12"},{"key":"2026061205052235000_16.6.e117593.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4486"},{"key":"2026061205052235000_16.6.e117593.32","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12526"},{"key":"2026061205052235000_16.6.e117593.33","unstructured":"Taylor DM , Paton C , Kapur S , eds. The Maudsley prescribing guidelines in psychiatry. 11th edn. Wiley-Blackwell, 2012."},{"key":"2026061205052235000_16.6.e117593.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030912","article-title":"Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)","volume":"9","author":"Moncrieff","year":"2019","journal-title":"BMJ Open"},{"key":"2026061205052235000_16.6.e117593.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3822-5","article-title":"To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial","volume":"21","author":"Begemann","year":"2020","journal-title":"Trials"},{"key":"2026061205052235000_16.6.e117593.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2007.11.012"},{"key":"2026061205052235000_16.6.e117593.37","doi-asserted-by":"crossref","unstructured":"Guy W . ECDEU assessment manual for psychopharmacology - revised. 1976.","DOI":"10.1037\/e591322011-001"},{"key":"2026061205052235000_16.6.e117593.38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.pra.0000400269.68160.e6","article-title":"Evaluation of the routine clinical use of the Brief Psychiatric Rating Scale (BPRS) and the Abnormal Involuntary Movement Scale (AIMS)","volume":"17","author":"Bark","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"2026061205052235000_16.6.e117593.39","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2091"},{"key":"2026061205052235000_16.6.e117593.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(95)71666-8"},{"key":"2026061205052235000_16.6.e117593.41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.alter.2012.08.004","article-title":"Une contribution \u00e0 l\u2019\u00e9valuation du handicap psychique: l\u2019\u00e9chelle d\u2019\u00e9valuation des processus du handicap psychique (EPHP)","volume":"6","author":"Passerieux","year":"2012","journal-title":"Alter"},{"key":"2026061205052235000_16.6.e117593.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(03)00086-5"},{"key":"2026061205052235000_16.6.e117593.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.04.011"},{"key":"2026061205052235000_16.6.e117593.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00355-9"},{"key":"2026061205052235000_16.6.e117593.45","unstructured":"EuroQol . Standardized instrument for use as a measure of health outcome (EQ-5D-5L). Available: www.euroqol.org [Accessed 10 Feb 2022]."},{"key":"2026061205052235000_16.6.e117593.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"2026061205052235000_16.6.e117593.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00130-9"},{"key":"2026061205052235000_16.6.e117593.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.12.470"},{"key":"2026061205052235000_16.6.e117593.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(99)90070-6"},{"key":"2026061205052235000_16.6.e117593.50","unstructured":"Loz\u00e8re C . ByCP: a Bayesian tool for the diagnosis of cycloid psychosis. 2024."},{"key":"2026061205052235000_16.6.e117593.51","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081124","article-title":"CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"key":"2026061205052235000_16.6.e117593.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.04.092"},{"key":"2026061205052235000_16.6.e117593.53","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.569912","article-title":"Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis","volume":"11","author":"Brandt","year":"2020","journal-title":"Front Psychiatry"},{"key":"2026061205052235000_16.6.e117593.54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2215-0366(22)00014-1","article-title":"Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis","volume":"9","author":"Brandt","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2026061205052235000_16.6.e117593.55","doi-asserted-by":"publisher","DOI":"10.1159\/000506868"},{"key":"2026061205052235000_16.6.e117593.56","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S2215-0366(20)30340-0","article-title":"Discontinuation of antipsychotic medication-time to rethink trial design","volume":"7","author":"Speyer","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2026061205052235000_16.6.e117593.57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2215-0366(22)00107-9","article-title":"Real-world effectiveness studies of low doses of antipsychotics","volume":"9","author":"Berna","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2026061205052235000_16.6.e117593.58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.2019.267","article-title":"In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine","volume":"217","author":"Luykx","year":"2020","journal-title":"Br J Psychiatry"},{"key":"2026061205052235000_16.6.e117593.59","doi-asserted-by":"publisher","DOI":"10.1192\/s0007125000292581"},{"key":"2026061205052235000_16.6.e117593.60","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.1.113"},{"key":"2026061205052235000_16.6.e117593.61","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/schbul\/sbv161","article-title":"Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms","volume":"42","author":"Dollfus","year":"2016","journal-title":"SCHBUL"},{"key":"2026061205052235000_16.6.e117593.62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb01487.x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:05:51Z","timestamp":1781265951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjopen-2026-117593"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117593","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}